在缺乏早孕期解剖筛查的情况下引入全民游离DNA后胎儿结构异常的诊断时机
荷兰自2021年起在全民游离DNA(cfDNA)检测同时提供早孕期解剖筛查(FTAS),此前仅提供中孕期解剖筛查(STAS)。该回顾性队列纳入2017至2020年间因疑似结构异常转诊的547例胎儿,发现未开展FTAS时多数胎儿异常直至中孕期或更晚才被检出,包括56%的「早孕期始终可检出」异常。
要点
- 未开展FTAS时,56%(37/66)的「早孕期始终可检出」异常在STAS时才被诊断。
- FTAS检出异常后的终止妊娠率为84.6%(11/13),STAS及之后检出者为29.3%(144/492)(p<0.01)。
- 492/534(92.1%)例异常得到确认,其中「始终可检出」占13.4%、「有时可检出」占61.6%、「不可检出」占25.0%。
核心结论
- 当FTAS未纳入筛查方案时,多数胎儿异常直至中孕期或更晚才被检出,包括56%的「早孕期始终可检出」异常。
研究设计与样本
- 回顾性队列纳入2017至2020年间因疑似结构异常在STAS前、中、后转诊的547例胎儿,并检索额外产前检查与出生后随访。
主要发现
- 547例妊娠中,13例(2.6%)接受FTAS,534例(97.6%)接受孕龄超声和STAS。
- 534例中492例(92.1%)异常得到确认;66例(13.4%)属「早孕期始终可检出」,303例(61.6%)属「有时可检出」,123例(25.0%)属「不可检出」。
- 「始终可检出」异常中,29/66(44%)在孕龄超声时诊断,37例(56%)在STAS时诊断。
- FTAS检出异常后的终止妊娠率为84.6%(11/13),STAS及之后检出者为29.3%(144/492)(p<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Since 2021, first-trimester anatomical screening (FTAS) is offered in the Netherlands alongside genome-wide cell-free DNA (cfDNA). Previously, only second-trimester anatomical screening (STAS) was offered. This study identifies structural abnormalities amenable to first-trimester diagnosis detected at/after STAS in the period following cfDNA implementation and preceding FTAS introduction. METHODS: This retrospective cohort includes 547 fetuses referred between 2017 and 2020 because of suspected structural abnormalities before/at/after STAS. Additional prenatal investigations and postnatal follow-up were searched. Abnormalities were classified into "always", "sometimes", and "never" detectable in the first-trimester based on a previously suggested classification. RESULTS: Of the 547 pregnancies, 13 (2.6%) received FTAS and 534 (97.6%) received a dating ultrasound and STAS. In 492/534 (92.1%) anomalies were confirmed; 66 (13.4%) belonged to the "always detectable" group in the first trimester, 303 (61.6%) to the "sometimes detectable", and 123 (25.0%) to the never detectable. Of the "always detectable" anomalies 29/66 (44%) were diagnosed during dating ultrasounds and 37 (56%) during STAS. The rate of termination of pregnancy for anomalies detected during FTAS and at/after STAS was 84.6% (n = 11/13) and 29.3% (n = 144/492) (p < 0.01). CONCLUSION: When FTAS is not part of screening paradigms, most fetal anomalies remain undetected until the second trimester or later in pregnancy, including 56% of anomalies "always detectable" in the first trimester.
引用
- Bardi F, Beekhuis AM, Bakker MK, et al. Timing of diagnosis of fetal structural abnormalities after the introduction of universal cell-free DNA in the absence of first-trimester anatomical screening. Prenat Diagn. 2022. PMID: 35971853. doi:10.1002/pd.6224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。